Efficacy of the NXSignal Device for the Treatment of Anterior Cruciate Ligament Injuries

Sponsor
University of Las Palmas de Gran Canaria (Other)
Overall Status
Recruiting
CT.gov ID
NCT05207943
Collaborator
(none)
40
1
3
19
2.1

Study Details

Study Description

Brief Summary

Injury to the anterior cruciate ligament (ACL) is very common among sports professionals and the general population [. Unlike other joint injuries, it is reversible, but it can damage adjacent tissues, particularly the meniscus, and catalyze knee osteoarthritis.

ACL injury produces instability, joint mechanical alteration, which can lead to degenerative joint diseases. The goal of treating the injury will be to prevent symptomatic instability, restore normal knee kinematics, and prevent degenerative joint disease .

Its usual treatment is surgical and therefore contributes to a significant cost for the health system, both for the surgeries themselves, and for the rehabilitation and subsequent recovery processes.

Within recovery therapies, in some cases, and given their popularity within the world of physiotherapy, electrotherapy techniques are proposed, primarily transcutaneous electrical nerve stimulation-type techniques with action on the muscular system and analgesia.

An early intervention with neuromuscular electrostimulation electrotherapy (NMES) combined with repeated exercises is effective for the recovery of strength and restoration of the biomechanical symmetry of the limb.

There is a diversity of opinions and disparate results regarding the use of this type of technique , in any case, it has been shown that electrical stimulation favors cell migration and joint tissue regeneration.

Condition or Disease Intervention/Treatment Phase
  • Device: Non-invasive Neuromodulation
  • Device: Placebo Non-invasive Neuromodulation
N/A

Detailed Description

The design of this study is a randomised, triple blind clinical trial with placebo control.

The general configuration of the study consists of capturing a group of patients treated with the same ACL surgical technique, operated on by the same surgeon, and including an additional treatment with the NESA XSIGNAL® device in a group of them.

For this, a double-blind capture system will be available (neither users nor specialists responsible for recovery will know which patients enter the complementary treatment) and two NESA XSIGNAL® devices operating double-blind (due to the imperceptivity of the stimulation performed, there will be a placebo machine and another that applies the treatment).

At the end of the study, the results obtained between the different groups of patients will be able to be compared; those additionally treated with a device, those treated with a placebo device and those in the standard rehabilitation procedure without a device.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
The intervention to which the subjects have been assigned, the specialist and the researcher who collects the information and performs the follow-ups will be blinded, using the simulated NESA XSIGNAL® device. Data analysis will also be performed in a blinded fashion. Patients will be assigned to NESA XSIGNAL® device 1 or 2. These devices will be labeled "1" and "2" and only the manufacturer will know which is the real or the simulated one. In the same way, to avoid subjective comparisons of the participants, in the same room, device 1 and 2 at the same time will not be used.
Primary Purpose:
Treatment
Official Title:
Efficacy of the NXSignal Device for the Treatment of Anterior Cruciate Ligament Injuries. Randomized Controlled Clinical Trial
Actual Study Start Date :
May 25, 2021
Anticipated Primary Completion Date :
Jul 25, 2022
Anticipated Study Completion Date :
Dec 25, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Non-invasive Neuromodulation

Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level and and in the popliteal fossa.

Device: Non-invasive Neuromodulation
The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA.

Sham Comparator: Placebo Non-invasive Neuromodulation

Placebo microcurrents Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level and in the popliteal fossa.

Device: Placebo Non-invasive Neuromodulation
The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents

No Intervention: Control

Participant will maintain the conventional rehabilitation treatment

Outcome Measures

Primary Outcome Measures

  1. Knee circumference [Up to 4 month]

    Centimeter measurement supra and infrapatellar with a tape measure with the leg in extension and without muscle contraction.

  2. Motor Control [Up to 4 month]

    It will be assessed through a dop jump, vertical jump test and Single leg squat.

  3. Functional ability [Up to 4 month]

    We will use the International Knee Documentation Committee (IKDC) questionnaire.

  4. Level of Pain [Up to 4 month]

    The Visual Analogue Scale (VAS) will be used to measure the perception of pain, which consists of a longitudinal line with 11 values ranging from 0 (none The Visual Analogue Scale (VAS) will be used to measure the perception of pain, which consists of a longitudinal line with 11 values ranging from 0 (no pain sensation) to 10 (maximum pain imaginable)

Secondary Outcome Measures

  1. Range of motion [Up to 4 month]

    To measure this variable, we will use a goniometer, which will align its fixed arm with the proximal segment of the limb, and the mobile arm with the distal segment, making its axis coincide with the axis of knee movement . 3 measurements will be carried out actively and another 3 passively, choosing the highest value obtained for each one. Flexion and extension movements will be analyzed.

  2. Brain activity [Up to 4 month]

    Brain activity will be measured through an Electroencephalogram (EEG). Corresponds to a technique for studying the electrical activity of the brain through electrodes located on the scalp The parameters to be measured are the waves beta (13-30 Hz), which are produced when a subject is awake doing cognitive work and perceiving environmental stimulus

  3. Quality of life related to health [Up to 4 month]

    The SF-12 scale will be applied

  4. Psychological perception test: [Up to 4 month]

    TSK-11SV questionnaire (version adapted to Spanish). It is an 11-item questionnaire about fear of movement or injury. Patients have to indicate their degree of agreement with each of the statements presented, using a Likert-type scale from 1 (totally disagree) to 4 (totally agree). This questionnaire is designed to also assess the avoidance dimensions of activity and harm, but in this work we will only use the total score. High scores indicate greater fear of movement

Eligibility Criteria

Criteria

Ages Eligible for Study:
16 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Over 16 years old

  • In normal conditions and mentally competent to participate in the study.

  • Not having previous knee surgeries.

  • In condition to complete the study questionnaires.

Exclusion Criteria:
  • Present some of the contraindications for a treatment with NESA XSIGNAL®: pacemakers, internal bleeding, do not apply electrodes on skin in poor condition, with ulcerations or wounds, acute febrile processes, acute thrombophlebitis and / or electricity phobia.

  • Not having signed the informed consent.

  • Urgent surgical interventions.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Las Palmas de Gran Canaria Las Palmas de Gran Canaria Las Palmas Spain 35016

Sponsors and Collaborators

  • University of Las Palmas de Gran Canaria

Investigators

  • Principal Investigator: Aníbal Báez Suárez, PhD, University of Las Palmas de Gran Canaria

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Aníbal Báez Suárez, Principal Investigator, University of Las Palmas de Gran Canaria
ClinicalTrials.gov Identifier:
NCT05207943
Other Study ID Numbers:
  • NESALCA
First Posted:
Jan 26, 2022
Last Update Posted:
May 3, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Aníbal Báez Suárez, Principal Investigator, University of Las Palmas de Gran Canaria
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 3, 2022